Current therapeutic options for IBD include corticosteroids, 5-aminosalicylic acid (5-ASA)-based drugs (sulfasalazine and mesalazine), immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), biologicals (anti-TNF-α monoclonal antibodies: adalimumab and infliximab, vedolizumab and ustekinumab), fecal microbiota transplantation, and surgical treatment (18). The gene discussed is TNF; the disease is inflammatory bowel disease.